Spectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Top Cited Papers
Open Access
- 5 February 2004
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (2) , 607-612
- https://doi.org/10.1002/art.20033
Abstract
Objective Mutations in the NALP3/CIAS1/PYPAF1 gene are associated with the autoinflammatory diseases Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), and neonatal-onset multisystem inflammatory disease (NOMID), which is also known as chronic infantile neurologic, cutaneous, articular (CINCA) syndrome. Molecular studies suggest that NALP3 is involved in the processing of interleukin-1β (IL-1β), prompting us to investigate whether IL-1 blockade may be therapeutic in patients with MWS. Methods We reviewed the clinical features of 3 members of a family, all of whom had MWS associated with the NALP3 variant V200M (also designated V198M), and evaluated the response of their inflammatory disease to treatment with the recombinant human IL-1 receptor antagonist anakinra. The subjects kept a diary of symptoms and underwent fortnightly clinical and laboratory assessments, including measurement of the serum amyloid A protein concentration. Results Each subject had fever, rashes, arthralgia, conjunctivitis, sensorineural deafness, and an intense acute-phase response characteristic of MWS. However, additional features were identified, including exacerbation of their disease by cold and neurologic manifestations, that have hitherto been described only in FCAS and NOMID, respectively. Clinical and serologic evidence of active inflammatory disease resolved rapidly and completely during treatment with anakinra. Conclusion The remarkable response of MWS to anakinra suggests that IL-1β has a fundamental role in the pathogenesis of inflammation associated with mutations in the NALP3 gene, and supports study of IL-1 inhibition in patients with NOMID/CINCA syndrome or FCAS. The clinical features of the various syndromes associated with mutations in the NALP3 gene may overlap to a greater extent than has previously been recognized.Keywords
This publication has 18 references indexed in Scilit:
- Interleukin-1–Receptor Antagonist in the Muckle–Wells SyndromeNew England Journal of Medicine, 2003
- NALPs: a novel protein family involved in inflammationNature Reviews Molecular Cell Biology, 2003
- De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal‐onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin‐associated autoinflammatory diseasesArthritis & Rheumatism, 2002
- Long‐term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin‐1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosisArthritis & Rheumatism, 2002
- New Mutations of CIAS1 That Are Responsible for Muckle-Wells Syndrome and Familial Cold Urticaria: A Novel Mutation Underlies Both SyndromesAmerican Journal of Human Genetics, 2002
- Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A proteinThe Lancet, 2001
- A new method of measuring C-reactive protein, with a low limit of detection, suitable for risk assessment of coronary heart diseaseScandinavian Journal of Clinical and Laboratory Investigation, 1999
- Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitorNature, 1990
- A Chronic, Infantile, Neurological, Cutaneous and Articular (CINCA) Syndrome. A Specific Entity Analysed in 30 PatientsScandinavian Journal of Rheumatology, 1987